A Randomized Hybrid‐Effectiveness Trial Comparing Pharmacogenomics ( PGx ) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care ( PGx ‐ ACT ) Trial
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70154 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von D Max Smith und 14 weiteren Autor:innen. Beteiligte Einrichtung: MedStar Health, Columbia, Maryland, USA. Hauptthemen laut MEDLINE: Chronic Pain, Pain Management, Pharmacogenetics. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Schmerzmanagement
Abstract (Originalsprache)
This trial aimed to identify the effects of providing pharmacogenomic (PGx) results and recommendations for patients with chronic pain treated in primary care practices compared to standard care. An open‐label, prospective, largely virtual, type‐2 hybrid effectiveness trial randomized participants to PGx or standard care arms. Adults with pain ≥ 3 months who were treated with tramadol, codeine, or hydrocodone enrolled. Alternative analgesics were recommended for CYP2D6 intermediate or poor metabolizers (IM/PMs). Prescribing decisions were at providers' discretion. The trial randomized 253 participants. A modified intent‐to‐treat primary analysis assessed change in pain intensity over 3 months among IM/PMs (PGx: 49; Standard care: 57). The PGx and standard care arms showed no difference in pain intensity change (−0.10 ± 0.63 vs. −0.21 ± 0.75 standard deviation; p = 0.74) or PGx‐aligned care (69% vs. 63%; standardized difference [SD] = 0.13). In IM/PMs, secondary analyses of pain intensity change suggested improvements with PGx‐aligned ( n = 70; −0.21 ± 0.70) vs. unaligned care ( n = 36; −0.06 ± 0.69) (SD = −0.22), with this difference increasing when examining IM/PMs with an analgesic change (aligned: n = 31, −0.28 ± 0.76; unaligned: n = 36, −0.06 ± 0.69; SD = −0.31). This approach to PGx implementation for chronic pain was not associated with different prescribing (i.e., similar proportions of PGx‐aligned care) or clinical outcomes. Secondary analyses suggest that prescribing aligned with PGx recommendations showed a small improvement in pain intensity. However, the proportion of patients with a clinically meaningful improvement (≥ 30%) in pain intensity was similar. Future efforts should identify effective implementation methods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MedStar Health, Columbia, Maryland, USA.
- Georgetown University Medical Center, Washington, DC, USA.
- Kailos Genetics, Inc., Huntsville, Alabama, USA.
- Georgetown University, Washington, DC, USA.
ORCID-Profile: D Max Smith, Sara Zifa, Sandra M Swain
Zitieren
APA
Smith, D. M., Beyene, R., Kolm, P., Young, T. A., Zifa, S., Natividad, V., Licata, A., Podolsky, R. H., Moore, T., Walsh, R., Deva, S., Walker, A. D., Jacobs, M. B., Peshkin, B. N., & Swain, S. M. (2025). A Randomized Hybrid‐Effectiveness Trial Comparing Pharmacogenomics ( PGx ) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care ( PGx ‐ ACT ) Trial. Clinical and Translational Science. https://doi.org/10.1111/cts.70154
Vancouver
Smith DM, Beyene R, Kolm P, Young TA, Zifa S, Natividad V, et al. A Randomized Hybrid‐Effectiveness Trial Comparing Pharmacogenomics ( PGx ) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care ( PGx ‐ ACT ) Trial. Clinical and Translational Science. 2025. doi:10.1111/cts.70154
BibTeX
@article{Smith2025,
author = {Smith, D Max and Beyene, Rut and Kolm, Paul and Young, Theresa A and Zifa, Sara and Natividad, Victoria and Licata, Andrea and Podolsky, Robert H and Moore, Troy and Walsh, Richard and Deva, Shikha and Walker, Alexander D and Jacobs, Michael B and Peshkin, Beth N and Swain, Sandra M},
title = {A Randomized Hybrid‐Effectiveness Trial Comparing Pharmacogenomics ( PGx ) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care ( PGx ‐ ACT ) Trial},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70154}
}
EUVIMED